Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations

NCT01024413 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

256

Enrollment

OTHER

Sponsor class

Conditions

Thoracic Neoplasms

Interventions

DRUG: erlotinib
DRUG: gefitinib

Sponsor

Chinese Society of Lung Cancer

Collaborators

[object Object]